HE4和CA125在卵巢肿瘤中的应用价值

Abstract
Figure/Table
References (13)
Related Citation (11)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To establish a simple and effectivemethod of predicting ovarianmalignant tumor by the detection of serum human epididymis protein 4　（HE4）and carbohydrate antigen 125　（CA125）of patients with ovarian tumor. Methods Serum HE4 and CA125 levels of 453 patients with ovarian tumor in our hospital from January 2013 to December 2014 were determined by Roche electrochemical luminescence method.Among them，80 patients with ovarian malignant tumor，373 patientswith ovarian benign tumors（including 135 cases of ovarian endometriosis cyst，116 cases of ovarian teratoma，45 cases ofmucous and serous cystadenoma，51 cases of ovarian simple cyst and 26 cases of corpus luteum cyst）.All the results were statistically analysed.Results Comparison of serum HE4 levels between patients with ovarian benign tumor，there was no statistically significant difference　（P＞0.05）；serum CA125 level of ovarian endometriosis cyst group was higher than that of other groups，the differencewas statistically significant（P＜0.05），Comparison between the rest of the group，there was no statistically significant difference　（P＞0.05）.If compared with benign ovarian tumors，serum HE4 cut-off value was 126.2 pmol/L，the clinical diagnosis sensitivity in patients with ovarian malignant tumorwas 72.5%.Conclusion HE4 and CA125 are better clinical auxiliary diagnosis indicator of ovarian tumor.

Key words： Ovarian tumor Human epididymis protein 4 Carbohydrate antigen 125 Tumormarker

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Feng
	HE Hua
	ZHU Ya-fei
	JIANG Li-xia
	WANG Qin

Cite this article:

LI Feng,HE Hua,ZHU Ya-fei, et al. The app lication value of tumormarkers HE4 and CA125 in ovarian tumor[J]. 中国当代医药, 2016, 23(26): 43-45.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I26/43

［1］	Rauh-Hain JA，Krivak TC，Del Carmen MG，et al.Ovarian cancer screening and early detection in the general population［J］.Rev Obstet Gynecol，2011，4（1）：15-21.
［2］	秦雪，刘鑫丽，王欣彦，等.血清CA125变化与上皮性卵巢癌预后及复发关系研究［J］.中国实用妇科与产科杂志，2016，32（5）：473-476.
［3］	Kenemans P，Yedema CA，Bon GG，et al.CA125 in gynecological pathology a review［J］.Eur JObstet Gynecol Reprod Biol，2003，49（1-2）：115-124.
［4］	Park Y，Lee JH，Hong DJ，et al.Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases［J］.Clin Biochem，2011，44（10-11）：884-888.
［7］	江涛，周芳芳，李军，等.血清人附睾蛋白4和糖类抗原125检测在早期卵巢癌诊断中的应用［J］.微循环学杂志，2016，26（2）：63-65
［10］	张松铭，汪丽霞.血清HE4与血清CA125在卵巢癌临床诊断的应用价值［J］.中国现代医生，2015，53（27）：112-114.
［13］	吴红娟，戴云先，刘广珍.血清HE4、CA125联合检测对卵巢癌的诊断价值［J］.中国医药科学，2015，5（23）：123-125.
［5］	Rosen DG，Wang L，Atkinson JN，et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer［J］.Gynecol Oncol，2005，99（2）：267-277.
［6］	Steffensen KD，Waldstrom M，Brandslund I，et al.Prognostic impact of prechemotherapy serum levels of HER2，CA125，and HE4 in ovarian cancer patients［J］.Int JGynecol Cancer，2011，21（6）：1040-1047.
［8］	Ferrar S，Braga F，LanzoniM，et al.Serum human epididymis protein 4 vs.carbohydrate antigen 125 for ovarian cancer diagnosis：asystematic review［J］.Clin Pathol，2013，66（4）：273-281.
［9］	Zheng H，Gao Y.Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease［J］.Int JGynecol Cancer，2012，22（6）：1000-1005.
［11］	Gislefoss RE，Langseth H，Bolstad N，et al.HE4 as an early detection biomarker of epithelial ovarian cancer：investigations in prediagnostic specimens from the Janus serumbank［J］.Int JGynecol Cancer，2015，25（9）：1608-1615.
［12］	Wilailak S，Chan KK，Chen CA，et al.Distinguishing benign form malignant pelvic mass utilizing an algorithm with HE4，menopausal status，and ultrasound findings［J］.JGynecol Oncol，2015，26（1）：46-53.